APEIRON Biologics licences MaxCyte’s electroporation platform
Viennese APEIRON Biologics and MaxCyte Inc have entered into licensing agreement covering the use of Maxcyte’s electroporation platform for APN401 development.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2084 entries already.
Entries by Thomas Gabrielczyk
Immatics launches US$250m Nasdaq-IPO
After closing the business merging with blank check company Arya Sciences Acquisition Corp, Immatics Inc has been listed on Nasdaq.
New insulin formulation allows faster blood sugar management
A new insulin formulation allows patients with diabetes to more quickly manage their blood sugar levels during mealtimes.
COVID-19: Lopinavir-ritonavir failed
Data from the UK’s RECOVERY trial demonstrate there was no clinical benefit from use of lopinavir-ritonavir in hospitalised COVID-19 patients.
EC pledges €4.9bn to grant access to medicines
Under the Coronavirus Global Response Framework, the European Commission is allocating further €4.9bn to assure access to COVID-19 countermeasures for poor countries.
An Outline of the German Medical Cannabis Market
The medical cannabis market has grown significantly in recent years. In Germany, the quantity of imported cannabis products has increased dramatically. In comparison to only 1.2 tons in 2017, German medical cannabis distributors imported about 3.13 metric tons of cannabis flowers for direct medical care of patients in 2018, while around 120 kg have been re-exported. In 2019, this amount doubled to around 6.7 tons.
BioGeneration Ventures closes BGV IV Fund at €105m
BioGeneration Ventures has closed its fourth VC fund for European start-ups (BGV IV) at €105m.
LSP leads €11m Series A round in OneProject
OneProjects Ltd, an Irish-German cardiac imaging specialist, has closed an €11m Series A financing led by Amsterdam-headquartered life sciences investor LSP.
Illumina and Epidarex Capital invest in post-Brexit UK
Illumina has opened its first accelerator outside the US in Cambridge to fund genomics start-ups. Meanwhile, Epidarex Capital has raised £102m for UK biotechs.
Novel adjuvant teases T cells to respond to HCV
Researchers from Italy, Denmark and the UK have devised a new vaccination strategy to tackle hepatitis C and boosting the required strong T cell response.